A desensitization-selective potentiator of AMPA-type glutamate receptors.
1: We examined the effects of PEPA, an allosteric potentiator of AMPA receptors, on AMPA receptor kinetics. 2: PEPA did not affect the deactivation of glutamate responses but potently attenuated the extent of receptor desensitization without slowing the onset of desensitization in most of the recombinant AMPA receptors (GluR1-flip, GluR1-flop, GluR3-flip, GluR3-flip+GluR2-flip, and GluR3-flop+GluR2-flop) expressed in Xenopus oocytes. For the GluR3-flop subunit, PEPA attenuated the extent of desensitization and only weakly prolonged deactivation (1.3 fold). 3: PEPA did not significantly affect recovery from desensitization in oocytes expressing GluR3-flip, GluR1-flop, and GluR1-flop, but weakly accelerated (2.6 fold) recovery from desensitization in oocytes expressing GluR3-flop. 4: PEPA's effect on desensitization of GluR3-flop-containing receptors is unique in that onset is very slow. 5: Simulation studies using simplified kinetic models for AMPA receptors are utilized to explore the differential effects of PEPA on GluR3-flip and -flop. It is possible to simulate the action on GluR3-flip by modulating two rate constants in a 12-state kinetic model. For simulation of the action on GluR3-flop, the 12-state kinetic model is not enough, and it is necessary to invoke a 13th state, a PEPA-bound receptor to which glutamate cannot bind. 6: These results suggest that attenuation of extent of desensitization represents the principal mechanism underlying the potentiation of AMPA receptors by PEPA, and that PEPA exhibits different mechanisms with respect to GluR3-flip and GluR3-flop.
Sekiguchi
Masayuki
M
Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry. 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, Japan. sekiguch@ncnp.go.jp
Nishikawa
Kaori
K
Aoki
Shunsuke
S
Wada
Keiji
K
D000494:Allosteric Regulation; D000818:Animals; D001581:Benzothiadiazines / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D009865:Oocytes / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010642:Phenoxyacetates / Q000494:pharmacology*; D011760:Pyrrolidinones / Q000494:pharmacology; D051381:Rats; D018091:Receptors, AMPA / Q000187:drug effects* / Q000502:physiology; D014981:Xenopus
C108189:4-(2-(phenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetamide; D001581:Benzothiadiazines; D010642:Phenoxyacetates; D011760:Pyrrolidinones; D018091:Receptors, AMPA; C104723:glutamate receptor ionotropic, AMPA 3; C036466:aniracetam; C004639:cyclothiazide